Standard BioTools (LAB, Financial) has introduced its first Proteomics Roundtable Series, a sequence of virtual events aimed at fostering dialogue in the burgeoning area of proteomics. This series is set to bring together leading experts and industry pioneers to discuss the latest research, advancements in technology, and practical applications of proteomics that are transforming healthcare.
The debut session, titled "Is More Really More? Evaluating the Case for High-Plex, High-Quality Proteomics," is scheduled for Friday, June 6, 2025, at 11:00 am ET. Stephen Williams, MD, PhD, Chief Medical Officer at Standard BioTools, will moderate a panel that includes researchers from the extensive EPIC cancer study, which spans three decades and involves 500,000 participants. These experts will share their discoveries of significant insights into cancer development from proteins that were previously undetectable in large population studies.
Notable speakers for this session include Elio Riboli, MD, a Professor of Cancer Epidemiology at Imperial College London, along with Marc Gunter, PhD, who serves as a Professor and Chair in Cancer Epidemiology and Prevention at the same institution. Additionally, Karl Smith-Byrne, DPhil, a Senior Molecular Epidemiologist at the University of Oxford, will join the discussion.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Standard BioTools Inc (LAB, Financial) is $2.38 with a high estimate of $2.50 and a low estimate of $2.25. The average target implies an upside of 124.06% from the current price of $1.06. More detailed estimate data can be found on the Standard BioTools Inc (LAB) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Standard BioTools Inc's (LAB, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Standard BioTools Inc (LAB, Financial) in one year is $0.84, suggesting a downside of 20.75% from the current price of $1.06. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Standard BioTools Inc (LAB) Summary page.
LAB Key Business Developments
Release Date: May 06, 2025
- Revenue: $40.8 million, down 10% year-over-year.
- Consumables Revenue: $14.5 million, down 16% year-over-year.
- Instruments Revenue: $7.8 million, up 24% year-over-year.
- Services Revenue: $17.6 million, down 16% year-over-year.
- Non-GAAP Gross Margin: 53.2%, down from 56.2% in the prior year.
- Non-GAAP Operating Expenses: $38.6 million, a decrease of 22% year-over-year.
- Net Loss: $26 million, an improvement of 19% year-over-year.
- Adjusted EBITDA Loss: $16.9 million, an improvement of 29% year-over-year.
- Cash and Equivalents: $261 million, with no material debt.
- Total Cash Burn: $34 million, a reduction from $101 million in the prior year.
- Adjusted Cash Burn: $31 million, a 33% reduction year-over-year.
- Full Year Revenue Guidance: $165 million to $175 million.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Standard BioTools Inc (LAB, Financial) delivered a solid first quarter with results on plan and in line despite a challenging operating environment.
- The company has a diversified portfolio and a disciplined operating model, which positions it well to navigate market dynamics.
- Recent high-impact product launches, including the new SomaScan offering, expand the company's reach in translational and clinical research.
- The company has a healthy cash position with $261 million in cash and equivalents and no material debt, providing financial stability.
- Non-GAAP operating expenses improved by 22% year-over-year, and adjusted EBITDA improved by 29%, reflecting effective cost management and operational improvements.
Negative Points
- Revenue for Q1 was $40.8 million, down 10% year-over-year, indicating challenges in maintaining growth.
- Consumables and service revenue were softer than usual, particularly in The Americas, showing variability and potential market weakness.
- The company faces headwinds from new tariff measures, adding complexity and potential cost pressures to global trade.
- US Academia funding delays and project timing issues negatively impacted revenue, particularly in consumables and services.
- Non-GAAP gross margins decreased to 53.2% from 56.2% year-over-year, impacted by lower volume and price realization on services.
